TITLE

BIOCUREX CANCER MONITORING DATA TO BE PRESENTED AT MEETING

PUB. DATE
September 2010
SOURCE
Worldwide Biotech;Sep2010, Vol. 22 Issue 9, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the International Society of Oncology and Biomarkers Congress Scientific Committee's acceptance of BioCurex Inc.'s presentation about the RECAF blood test potential to monitor cancer recurrence and treatment. BioCurex chief executive officer Ricardo Moro has also been invited to co-chair a panel discussion on biomarker statistics and present challenges in developing cancer markers at the meeting, which will be held in September 2010 in Munich, Germany. The importance of an affordable and reliable cancer marker test is described.
ACCESSION #
53281241

 

Related Articles

  • Q&A: Victor Velculescu. Bender, Eric // Nature;5/14/2015 Supplement, Vol. 521 Issue 7551, pS9 

    An interview with oncologist Victor Velculescu is presented. When asked what circulating tumor DNA (ctDNA) was and how it could help in cancer therapeutics, he said ctDNA was fragments of DNA that escaped from tumors into the bloodstream which provides genetic clues to detect and analyse the...

  • TROP2 expression as prognostic marker for gastric carcinoma. G Mühlmann // Journal of Clinical Pathology;Feb2009, Vol. 62 Issue 2, p152 

    BACKGROUND: In gastric cancer the recurrence rate is unacceptably high, even after R0 resection and (neo)adjuvant chemotherapy. Therefore, there is an urgent need for identification of predictive and/or prognostic biomarkers to select high-risk patients who might benefit from additional...

  • Mammostrat helps quantify likelihood of breast cancer recurrence. PEDERSEN, AMANDA // Biomedical Business & Technology;Jan2011, Vol. 34 Issue 1, p25 

    This article announces the commercial launch by Clarient of Insight Dx Mammostrat, a new test aimed at detecting the likelihood of breast cancer recurrence following surgery and initial treatment. Five biomakers are used by the Mammostrat test. According to Rob Seitz of Clarient, the Mammostrat...

  • BioCurex Updates Its Shareholders.  // Biotech Financial Reports;Jul2011, Vol. 18 Issue 7, p5 

    The article reports that chief executive officer (CEO) Ricardo Moro, of cancer diagnostics company BioCurex Inc., has sent a letter to update shareholders on the company's current and future programs. The letter provides information on programs including synthetic peptide for canine RECAF tests,...

  • New blood test could predict breast cancer relapse months before tumours show on scan.  // Nursing Standard;9/2/2015, Vol. 30 Issue 1, p14 

    The article reports on the development of a blood test capable of predicting breast cancer relapse months before tumours show on hospital scans by researchers at The Institute of Cancer Research, a public research institute, and The Royal Marsden National Health Service Foundation Trust in England.

  • Red Blood cell distribution width: an emerging diagnostic factor of acute appendicitis? Karagöz, Ergenekon; Tanoglu, Alpaslan // World Journal of Emergency Surgery;2013, Vol. 8 Issue 1, p54 

    Acute appendicitis is the most common surgical abdominal emergency. Immediate diagnosis of this disease is crucial, because this condition can lead to appendiceal perforation, potential peritonitis, and even death. We read with great interest the article 'The role of red cell distribution width...

  • Saliva: A fluid in search of a diagnostic use. Jia Liu // Dental Hypotheses;Oct-Dec2015, Vol. 6 Issue 4, p156 

    Since saliva has been studied for more than 50 years and is relatively easy to collect, it is reasonable to ask why saliva is not in wider use as a diagnostic fluid. Here we discuss the criteria for diagnostic tests for diseases, barriers to use saliva for diagnostic testing, and the possibility...

  • Translational Psychiatry: Biomarkers for autism discovered.  // Biomedical Market Newsletter;3/28/2012, Vol. 21, p1 

    The article focuses on a study which discovered new biomarkers from a tiny blood sample to treat autism.

  • Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma. Yáñez, Yania; Grau, Elena; Oltra, Silvestre; Cañete, Adela; Martínez, Francisco; Orellana, Carmen; Noguera, Rosa; Palanca, Sarai; Castel, Victoria // Journal of Cancer Research & Clinical Oncology;Aug2011, Vol. 137 Issue 8, p1263 

    Purpose: In non-metastatic neuroblastoma (NB), the identification of the cases that require more intensive treatment is still difficult. Minimal disease (MD) and minimal residual disease (MRD) detection in outcome prediction seems to be important in advanced neuroblastoma, but there are not many...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics